Laurent A Decosterd
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial
Sculier D, Calmy A, Egger M, Limacher A, Schmid P, Günthard H, Decosterd L, Metzner K, Buzzi M, Cavassini M, Veraguth K, Braun D, Bernasconi E, Stoeckle M, Marinosci A, Yerly S, Wandeler G, and the Swiss HIV Cohort Study (SHCS). Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. PLoS Med 2020; 17:e1003421.
10.11.2020Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial
10.11.2020PLoS Med 2020; 17:e1003421
Sculier Delphine, Calmy Alexandra, Egger Matthias, Limacher Andreas, Schmid Patrick, Günthard Huldrych F, Decosterd Laurent A, Metzner Karin J, Buzzi Marta, Cavassini Matthias, Veraguth Katja, Braun Dominique L, Bernasconi Enos, Stoeckle Marcel, Marinosci Annalisa, Yerly Sabine, Wandeler Gilles, and the Swiss HIV Cohort Study (SHCS)
Privacy-preserving genomic testing in the clinic: a model using HIV treatment
McLaren P, Hubaux J, Fellay J, Decosterd L, Di Benedetto C, Schmid P, Marzolini C, Doco-Lecompte T, Furrer H, Cavassini M, Günthard H, Vallet Y, Delgado M, Bartha I, Ayday E, Rotger M, Aouri M, Raisaro J, Telenti A. Privacy-preserving genomic testing in the clinic: a model using HIV treatment. Genet Med 2016; 18:814-22.
14.01.2016Privacy-preserving genomic testing in the clinic: a model using HIV treatment
14.01.2016Genet Med 2016; 18:814-22
McLaren Paul J, Hubaux Jean-Pierre, Fellay Jacques, Decosterd Laurent A, Di Benedetto Caroline, Schmid Patrick, Marzolini Catia, Doco-Lecompte Thanh, Furrer Hansjakob, Cavassini Matthias, Günthard Huldrych F, Vallet Yannick, Delgado Maria B, Bartha István, Ayday Erman, Rotger Margalida, Aouri Manel, Raisaro Jean Louis, Telenti Amalio
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine and Cerebro-Spinal Fluid
Aouri M, Rotger M, Telenti A, Buclin T, Günthard H, Vernazza P, Henry H, Yerly S, Anagnostopoulos A, Cavassini M, Ternon B, Barcelo C, Decosterd L. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine and Cerebro-Spinal Fluid. Drug Metab Dispos 2015
09.11.2015In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine and Cerebro-Spinal Fluid
09.11.2015Drug Metab Dispos 2015
Aouri Manel, Rotger Margalida, Telenti Amalio, Buclin Thierry, Günthard Huldrych F, Vernazza Pietro, Henry Hugues, Yerly Sabine, Anagnostopoulos Alexia, Cavassini Matthias, Ternon Beatrice, Barcelo Catalina, Decosterd Laurent A
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid
Cusini A, Günthard H, Opravil M, Gutmann C, Zenger F, Klimkait T, Cavassini M, Gaudenz R, Hirschel B, Widmer N, Rohrbach J, Fux C, Ledergerber B, Decosterd L, Yerly S, Vernazza P, Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013; 62:28-35.
01.01.2013Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid
01.01.2013J Acquir Immune Defic Syndr 2013; 62:28-35
Cusini Alexia, Günthard Huldyrich F, Opravil Milos, Gutmann Christine, Zenger Franziska, Klimkait Thomas, Cavassini Matthias, Gaudenz Roman, Hirschel Bernhard, Widmer Nicolas, Rohrbach Janine, Fux Christoph A, Ledergerber Bruno, Decosterd Laurent A, Yerly Sabine, Vernazza Pietro, Swiss HIV Cohort Study
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
Lubomirov R, Telenti A, Csajka C, Decosterd L, Buclin T, Descombes P, Rentsch K, Ledergerber B, Cavassini M, Calmy A, Vernazza P, Furrer H, Marzolini C, Martinez R, Colombo S, Fayet A, di Iulio J, Swiss HIV Cohort Study. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-30.
01.04.2010ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
01.04.2010Pharmacogenet Genomics 2010; 20:217-30
Lubomirov Rubin, Telenti Amalio, Csajka Chantal, Decosterd Laurent A, Buclin Thierry, Descombes Patrick, Rentsch Katharina, Ledergerber Bruno, Cavassini Matthias, Calmy Alexandra, Vernazza Pietro, Furrer Hansjakob, Marzolini Catia, Martinez Raquel, Colombo Sara, Fayet Aurélie, di Iulio Julia, Swiss HIV Cohort Study
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
Fellay J, Telenti A, Eap C, Vernazza P, Schinkel A, Ruiz L, Retelska D, Pantaleo G, Opravil M, Furrer H, Decosterd L, Chave J, Buclin T, Back D, Meaden E, Marzolini C, Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-6.
05.01.2002Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
05.01.2002Lancet 2002; 359:30-6
Fellay Jacques, Telenti Amalio, Eap Chin B, Vernazza Pietro, Schinkel Alfred H, Ruiz Lidia, Retelska Dorota, Pantaleo Giuseppe, Opravil Milos, Furrer Hansjakob, Decosterd Laurent A, Chave Jean Philippe, Buclin Thierry, Back David J, Meaden Emma R, Marzolini Catia, Swiss HIV Cohort Study